Table 1.
VARIABLES ASSOCIATED WITH DISEASE RESOLUTION AND TIME TO RESOLUTION
| Healing Status | Time to Resolution | |||||
|---|---|---|---|---|---|---|
| Complete Resolution |
Disease Improvement |
Disease Progression |
P Value | Cox Hazard Ratio (95% CI) | Cox P Value | |
| Age (yr) | 72.0 | 71.6 | 70.4 | .489 | 1.00 (0.98–1.02) | .772 |
| Gender, n (%) | .176 | 0.81 (0.49–1.65) | .424 | |||
| Women | 63 (76) | 15 (18) | 5 (6) | |||
| Men | 20 (59) | 10 (29) | 4 (12) | |||
| Anatomic site, n (%) | .949 | 1.01 (0.64–1.59) | .968 | |||
| Maxilla | 30 (70) | 10 (23) | 3 (7) | |||
| Mandible | 53 (72) | 15 (20) | 6 (8) | |||
| Condition, n (%) | .487 | 1.20 (0.77–1.87) | .417 | |||
| Osteoporosis | 34 (75) | 7 (16) | 4 (9) | |||
| Malignancy | 49 (68) | 18 (25) | 5 (7) | |||
| Antiresorptive drug, n (%) | .079 | 0.80 (0.45–1.40) | .434 | |||
| Bisphosphonate | 65 (67) | 24 (24) | 9 (9) | |||
| Alendronate | 31 (72) | 10 (23) | 2 (5) | |||
| Zoledronate | 31 (62) | 13 (26) | 6 (12) | |||
| Other | 3 (60) | 1 (20) | 1 (20) | |||
| Denosumab | 16 (94) | 1 (6) | 0 | |||
| Prolia* | 10 (100) | 0 | 0 | |||
| Xgeva* | 6 (86) | 1 (14) | 0 | |||
| Unknown | 2 (100) | 0 | 0 | |||
| Staging, n (%) | .452 | 0.82 (0.58–1.18) | .286 | |||
| Stage 1 | 47 (72) | 16 (25) | 2 (3) | |||
| Stage 2 | 32 (70) | 9 (20) | 5 (10) | |||
| Stage 3 | 4 (67) | 0 | 2 (33) | |||
| Time on antiresorptive drug (yr) | 5.5 | 3.7 | 4.8 | .819 | 1.01 (0.96–1.06) | .806 |
| Inciting event, n (%) | .269 | — | .686 | |||
| Extraction | 50 (76) | 10 (15) | 6 (9) | |||
| Spontaneous | 16 (68) | 9 (32) | 0 | |||
| Dental disease | 7 (64) | 3 (27) | 1 (9) | |||
| Implant | 7 (64) | 2 (18) | 2 (18) | |||
| Denture | 3 (75) | 1 (25) | 0 | |||
| Wound care score | 2.4 | 3.7 | 4.8 | <.001 | 0.32 (0.22–0.46) | <.001 |
Abbreviation: CI, confidence interval.
*
Amgen, Inc (Thousand Oaks, CA).